Literature DB >> 6989826

Degradation of type IV (basement membrane) collagen by a proteinase isolated from human polymorphonuclear leukocyte granules.

C L Mainardi, S N Dixit, A H Kang.   

Abstract

A serine esterase with potent proteolytic activity against native bovine lens capsule type IV collagen was isolated and purified from extract of human polymorphonuclear leukocytes (PMN). The type IV collagenolytic activity co-purified with N-t-benzyloxycarbonyl-L-alanine nitroanilidase, and was inhibited by phenylmethanesulfonyl fluoride and N-acetyl-Ala-Ala-Ala-Ala chloromethyl ketone. In addition, the purified enzyme had elastolytic activity, reacted with a specific antibody to PMN elastase, and, therefore, appeared to be identical with this enzyme. A simple, reproducible assay for the detection of type IV collagenase activity using insoluble bovine anterior lens capsule collagen was defined. Sodium dodecyl sulfate polyacrylamide gel electrophoresis revealed that the enzyme released large molecular weight peptides (greater than 30,000) from the insoluble substrate. The enzyme was also active against native, pepsin-solubilized type IV collagen; five reaction products could be identified. These data suggest that PMN elastase may be involved in the degradation of basement membrane collagen in physiologic and pathologic states.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6989826

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy.

Authors:  A Gandorfer; E Putz; U Welge-Lüssen; M Grüterich; M Ulbig; A Kampik
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

2.  Collagenase derived from human fibrosarcoma is responsible for degradation of basement membranes.

Authors:  N Slade; S Levanat; S Spaventi; K Pavelić
Journal:  Int J Exp Pathol       Date:  1991-12       Impact factor: 1.925

3.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Arch Biochem Biophys       Date:  2006-11-17       Impact factor: 4.013

4.  Blockade of neutrophil elastase attenuates severe liver injury in hepatitis B transgenic mice.

Authors:  Shinji Takai; Kiminori Kimura; Masahito Nagaki; Shinichi Satake; Kazuhiro Kakimi; Hisataka Moriwaki
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development.

Authors:  H G Welgus; E J Campbell; J D Cury; A Z Eisen; R M Senior; S M Wilhelm; G I Goldberg
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

6.  MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK.

Authors:  Tracy Dodd; Rashmi Jadhav; Luke Wiggins; James Stewart; Erika Smith; James C Russell; Petra Rocic
Journal:  J Mol Cell Cardiol       Date:  2011-08-22       Impact factor: 5.000

7.  Cleavage of native type I collagen by human neutrophil elastase.

Authors:  W Kafienah; D J Buttle; D Burnett; A P Hollander
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

Review 8.  The role of cell adhesion proteins--laminin and fibronectin--in the movement of malignant and metastatic cells.

Authors:  J B McCarthy; M L Basara; S L Palm; D F Sas; L T Furcht
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

9.  Degradation of basement membrane laminin by human neutrophil elastase and cathepsin G.

Authors:  L W Heck; W D Blackburn; M H Irwin; D R Abrahamson
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

10.  Presence, activities, and molecular forms of cathepsin G, elastase, alpha 1-antitrypsin, and alpha 1-antichymotrypsin in bronchiectasis.

Authors:  R Sepper; Y T Konttinen; T Ingman; T Sorsa
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.